Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$320.88
Market cap
$23.24B
P/E Ratio
47.12
Dividend/share
$0.81
EPS
$6.81
Enterprise value
$23.05B
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe,
Highlights
West Pharmaceutical Services's quick ratio has increased by 35% from the previous quarter but it has decreased by 26% YoY
WST's equity is up by 7% since the previous quarter but it is down by 4% year-on-year
The net income has contracted by 11% YoY and by 4.8% from the previous quarter
The gross profit has contracted by 10% YoY and by 2.3% from the previous quarter
Key stats
What are the main financial stats of WST
Market
Valuations
Earnings
Shares outstanding
72.42M
Market cap
$23.24B
Enterprise value
$23.05B
Price to earnings (P/E)
47.12
Price to book (P/B)
8.46
Price to sales (P/S)
8.12
EV/EBIT
37.8
EV/EBITDA
30.32
EV/Sales
8.01
Revenue
$2.88B
EBIT
$609.8M
EBITDA
$760.4M
Free cash flow
$321.6M
Per share
Balance sheet
Liquidity
EPS
$6.81
Free cash flow per share
$4.42
Book value per share
$37.94
Revenue per share
$39.51
TBVPS
$48.82
Total assets
$3.68B
Total liabilities
$923M
Debt
$304.8M
Equity
$2.75B
Working capital
$1.03B
Debt to equity
0.11
Current ratio
3
Quick ratio
1.97
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
26.4%
Gross margin
34.9%
Net margin
17.4%
Operating margin
19.9%
Return on assets
13.7%
Return on equity
18.3%
Return on invested capital
23.3%
Return on capital employed
19.3%
Return on sales
21.2%
Dividend yield
0.25%
DPS
$0.81
Payout ratio
11.9%
WST stock price
How has the West Pharmaceutical Services stock price performed over time
Intraday
2.96%
1 week
-5.1%
1 month
11.71%
1 year
-8.97%
YTD
-8.87%
QTD
6.9%
Financial performance
How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.88B
Gross profit
$1B
Operating income
$571.2M
Net income
$499.6M
Gross margin
34.9%
Net margin
17.4%
The net income has contracted by 11% YoY and by 4.8% from the previous quarter
WST's operating income is down by 11% YoY and by 2.7% from the previous quarter
The operating margin has declined by 10% year-on-year and by 2.5% since the previous quarter
The gross profit has contracted by 10% YoY and by 2.3% from the previous quarter
Growth
What is West Pharmaceutical Services's growth rate over time
Valuation
What is West Pharmaceutical Services stock price valuation
P/E
47.12
P/B
8.46
P/S
8.12
EV/EBIT
37.8
EV/EBITDA
30.32
EV/Sales
8.01
WST's EPS is down by 9% year-on-year and by 4.2% since the previous quarter
The price to book (P/B) is 17% lower than the 5-year quarterly average of 10.2 and 9% lower than the last 4 quarters average of 9.3
WST's equity is up by 7% since the previous quarter but it is down by 4% year-on-year
The P/S is 9% below the 5-year quarterly average of 8.9 and 7% below the last 4 quarters average of 8.7
Efficiency
How efficient is West Pharmaceutical Services business performance
WST's return on invested capital is down by 16% year-on-year and by 7% since the previous quarter
The company's return on assets fell by 10% YoY and by 4.2% QoQ
West Pharmaceutical Services's ROE has decreased by 9% YoY and by 4.2% from the previous quarter
WST's return on sales is down by 9% year-on-year and by 3.6% since the previous quarter
Dividends
What is WST's dividend history
DPS
$0.81
Dividend yield
0.25%
Payout ratio
11.9%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did West Pharmaceutical Services financials performed over time
West Pharmaceutical Services's quick ratio has increased by 35% from the previous quarter but it has decreased by 26% YoY
West Pharmaceutical Services's current ratio has increased by 28% QoQ but it has decreased by 19% YoY
WST's debt is 89% smaller than its equity
The debt to equity has contracted by 8% from the previous quarter
WST's equity is up by 7% since the previous quarter but it is down by 4% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.